KR102033964B1 - 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 - Google Patents
가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 Download PDFInfo
- Publication number
- KR102033964B1 KR102033964B1 KR1020180007310A KR20180007310A KR102033964B1 KR 102033964 B1 KR102033964 B1 KR 102033964B1 KR 1020180007310 A KR1020180007310 A KR 1020180007310A KR 20180007310 A KR20180007310 A KR 20180007310A KR 102033964 B1 KR102033964 B1 KR 102033964B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- gadoteridol
- represented
- lithium
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DPNNNPAKRZOSMO-UHFFFAOYSA-K gadoteridol Chemical compound [Gd+3].CC(O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 DPNNNPAKRZOSMO-UHFFFAOYSA-K 0.000 title claims abstract description 45
- 229960005451 gadoteridol Drugs 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 19
- FXGAYTVRICVFGL-UHFFFAOYSA-N 1-(1,4,7,10-tetrazacyclododec-1-yl)propan-2-ol Chemical compound CC(O)CN1CCNCCNCCNCC1 FXGAYTVRICVFGL-UHFFFAOYSA-N 0.000 claims abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- -1 lithium halogen Chemical class 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 229910052744 lithium Inorganic materials 0.000 claims description 9
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 7
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 7
- 229940075613 gadolinium oxide Drugs 0.000 claims description 6
- 229910001938 gadolinium oxide Inorganic materials 0.000 claims description 6
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000376 reactant Substances 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Chemical group 0.000 claims description 2
- 239000002616 MRI contrast agent Substances 0.000 abstract description 6
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 description 6
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 description 6
- 229910052688 Gadolinium Inorganic materials 0.000 description 5
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- HRAIEHCQDDIRTO-UHFFFAOYSA-N 1-(1,4,7,10-tetrazacyclododec-1-yl)propan-2-ol;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.CC(O)CN1CCNCCNCCNCC1 HRAIEHCQDDIRTO-UHFFFAOYSA-N 0.000 description 3
- 238000007126 N-alkylation reaction Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical group CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- ZZVAPPCNIIULIO-UHFFFAOYSA-N dodecane;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.CCCCCCCCCCCC ZZVAPPCNIIULIO-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960003411 gadobutrol Drugs 0.000 description 1
- LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
- 삭제
- 삭제
- 삭제
- 1,4,7,10-테트라아자사이클로도데칸과 리튬-할로겐염을 반응시켜 싸이클렌-리튬할로겐 착체를 제조하고, 이를 프로필렌 옥사이드와 반응시켜 하기 화학식 2로 표시되는 10-(2-하이드록실프로필)-1,4,7,10-테트라아자싸이클로도데칸-리튬할로겐 착체를 얻는 단계;
[화학식 2]
(상기 화학식 2에서, X는 불소, 염소, 브롬, 요오드이다.)
상기 화학식 2로 표시되는 리튬할로겐 착체와 염산을 반응시켜, 하기 화학식 3으로 표시되는 가도테리돌 중간체(10-(2-하이드록실프로필)-1,4,7,10-테트라아자싸이클로도데칸 4염산염)를 얻는 단계;
상기 화학식 2로 표시되는 리튬할로겐 착체와 염산의 반응물을 여과하여 화학식 3으로 표시되는 가도테리돌 중간체를 결정 형태로 얻는 단계;
[화학식 3]
상기 화학식 3으로 표시되는 가도테리돌 중간체를 2-클로로아세트산으로 알킬화 하여, 하기 화학식 4로 표시되는 테리돌을 얻는 단계; 및
[화학식 4]
상기 화학식 4로 표시되는 테리돌과 가돌리늄 옥사이드를 반응시켜, 하기 화학식 5로 표시되는 가도테리돌을 합성한 후, 유기 용매를 추가하여 고체로 석출하는 단계; 를 포함하며,
상기 가도테리돌 중간체와 2-클로로아세트산의 반응물을 나노필터를 사용하여 정제하는 것인, 가도테리돌 제조방법.
[화학식 5]
- 삭제
- 제4항에 있어서, 상기 유기용매는 아세톤인 것인, 가도테리돌의 제조 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180007310A KR102033964B1 (ko) | 2018-01-19 | 2018-01-19 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
PCT/KR2019/000483 WO2019143073A1 (ko) | 2018-01-19 | 2019-01-11 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
JP2020539756A JP7032550B2 (ja) | 2018-01-19 | 2019-01-11 | ガドテリドール中間体及びこれを利用したガドテリドール製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180007310A KR102033964B1 (ko) | 2018-01-19 | 2018-01-19 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190088792A KR20190088792A (ko) | 2019-07-29 |
KR102033964B1 true KR102033964B1 (ko) | 2019-10-18 |
Family
ID=67301080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180007310A Active KR102033964B1 (ko) | 2018-01-19 | 2018-01-19 | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP7032550B2 (ko) |
KR (1) | KR102033964B1 (ko) |
WO (1) | WO2019143073A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114249701B (zh) * | 2022-01-04 | 2024-11-26 | 安徽普利药业有限公司 | 一种钆特醇化合物的晶型及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100269081B1 (ko) * | 1992-06-04 | 2000-10-16 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | N-베타-히드록시알킬-트리-n-카르복시알킬-1,4,7,10-테트라아자시클로도데칸및n-베타-히드록시알킬-트리-n-카르복시알킬-1,4,8,11-테트라아자시클로테트라데칸유도체및그들의금속착화합물의제조방법 |
JP2002508755A (ja) * | 1997-06-02 | 2002-03-19 | シェリング アクチェンゲゼルシャフト | モノ−及び1、7−ビス−n−ヒドロキシアルキル−シクレン並びにそのリチウム塩錯体の製造 |
JP3471836B2 (ja) * | 1991-12-06 | 2003-12-02 | シエーリング アクチエンゲゼルシヤフト | モノ−n−置換されたテトラアザシクロドデカン誘導体および−テトラデカン誘導体の製造方法、ならびに診断および治療用の金属錯体の製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4237943C2 (de) * | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
JPH09268131A (ja) * | 1996-01-31 | 1997-10-14 | Nihon Medi Physics Co Ltd | 高濃度核磁気共鳴造影剤 |
DE10064467C2 (de) * | 2000-12-15 | 2002-10-31 | Schering Ag | Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung |
CN106543094A (zh) | 2016-11-04 | 2017-03-29 | 嘉实(湖南)医药科技有限公司 | 高纯度钆布醇的制备方法 |
-
2018
- 2018-01-19 KR KR1020180007310A patent/KR102033964B1/ko active Active
-
2019
- 2019-01-11 WO PCT/KR2019/000483 patent/WO2019143073A1/ko active Application Filing
- 2019-01-11 JP JP2020539756A patent/JP7032550B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3471836B2 (ja) * | 1991-12-06 | 2003-12-02 | シエーリング アクチエンゲゼルシヤフト | モノ−n−置換されたテトラアザシクロドデカン誘導体および−テトラデカン誘導体の製造方法、ならびに診断および治療用の金属錯体の製造方法 |
KR100269081B1 (ko) * | 1992-06-04 | 2000-10-16 | 에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 | N-베타-히드록시알킬-트리-n-카르복시알킬-1,4,7,10-테트라아자시클로도데칸및n-베타-히드록시알킬-트리-n-카르복시알킬-1,4,8,11-테트라아자시클로테트라데칸유도체및그들의금속착화합물의제조방법 |
JP2002508755A (ja) * | 1997-06-02 | 2002-03-19 | シェリング アクチェンゲゼルシャフト | モノ−及び1、7−ビス−n−ヒドロキシアルキル−シクレン並びにそのリチウム塩錯体の製造 |
Also Published As
Publication number | Publication date |
---|---|
JP2021511322A (ja) | 2021-05-06 |
KR20190088792A (ko) | 2019-07-29 |
JP7032550B2 (ja) | 2022-03-08 |
WO2019143073A1 (ko) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL197402A (en) | Process for preparing n-alkyl naltrexone halides | |
CA3074161C (en) | Gadobutrol intermediate and gadobutrol production method using same | |
EP3733651B1 (en) | Method for producing calcobutrol | |
KR102033964B1 (ko) | 가도테리돌 중간체 및 이를 이용한 가도테리돌 제조방법 | |
JP2008538371A (ja) | シクレン誘導体の合成 | |
US4791210A (en) | Process for the production of 5-methyltetrazole | |
US11319294B2 (en) | Method for manufacturing calteridol | |
EP3875453A1 (en) | Method for manufacturing calcobutrol | |
JPH0351713B2 (ko) | ||
KR20070110617A (ko) | 로사탄의 개선된 제조방법 | |
KR102445756B1 (ko) | 가도테레이트 메글루민 중간체인 가도테릭산 및 이를 이용한 가도테레이트 메글루민 제조 방법 | |
KR100701420B1 (ko) | 비페닐테트라졸 유도체의 제조방법 | |
JP2002069050A (ja) | ヒドラゾジカルボンアミドの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20180119 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190601 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190925 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20191014 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20191014 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20220927 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20230704 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20240808 Start annual number: 6 End annual number: 6 |